COVID-19 vaccination: challenges in the pediatric population by Alice Nicoleta Azoicai, Ingrith Miron, Ancuta Lupu, Monica Mihaela Alexoae, Iuliana Magdalena Starcea, Mirabela Alecsa, Vasile Valeriu Lupu, Ciprian Danielescu, Alin Horatiu Nedelcu, Delia Lidia Salaru, Felicia Dragan, Ileana Ioniuc

“…In response, several pharmaceutical companies rapidly leveraged their resources to develop vaccines within a very short period of time, leading to the introduction of new, improved, and combination vaccines for community-wide immunization. …”
Get full text

Façonner la prescription, influencer les médecins by Jérôme Greffion, Thomas Breda

“…They represent at least 20 % of the turnover of this sector and drug detailing request up to 40 % of the total staff of the large pharmaceutical companies, which have become marketing giants. …”
Get full text

Signaling Pathway Puts the Break on Fat Cell Formation by Ormond A. MacDougald

“…These environmental factors may be complicated in some individuals by an unfavorable genetic predisposition. Pharmaceutical companies lead active research programs to identify drugs that target weight control centers in the body and which may help individuals control their weight; however, no satisfactory magic bullet to fight obesity has yet come through the pipeline [7,8].…”
Get full text

The potential of three-dimensional printing for pediatric oral solid dosage forms by Kreft Klemen, Fanous Marina, Möckel Volker

“…In this setup, pharmaceutical companies would routinely provide materials and instructions for 3D printing, while specialized compounding centers or hospital pharmacies perform the printing of medication. …”
Get full text

Dangerous Liaisons? by Norman L Jones

“…A case in point was a few days last month during which I attended a well-sponsored meeting of the Ontario Lung Association, reviewed a couple of papers reporting drug trials, read of the threats of litigation made by pharmaceutical companies to two Ontario researchers, heard of a public apology made by the New England Journal of Medicine regarding reviewers' conflicts of interest and received a critical letter from Dr Rob McFadden, an associate editor of the Canadian Respiratory Journal, about a sponsored publication that accompanied the last issue of 1999. …”
Get full text

Reform and Development of Rare Diseases Drug Evaluation and Approval in China by HUANG Guo, YANG Zhimin, TANG Ling, ZHANG Jie, AI Xing, SE RI Geleng, ZHAO Tian

“…Due to the small number of patients and limited market demand, pharmaceutical companies don′t have enough incentives and resources to invest in drug research and development. …”
Get full text

Advancing the development of real-world data for healthcare research in China: challenges and opportunities by Jun Zhang, Eric Wu, Jia Zhong, Honghao Fang, Larry Liu, Jipan Xie

“…A workshop with 30 representatives from healthcare research agencies, technology companies focused on healthcare big data and pharmaceutical companies was held in December 2020 to identify strategies to overcome the barriers associated with the usability and quality of RWD in China. …”
Get full text

Accessibility of COVID-19 Vaccines in African Countries: A System Dynamics Model Examining Income, Logistics, and Governance by Oya Öztürk, Muhammed Çelik

“…To combat the COVID-19 pandemic, pharmaceutical companies, biotech companies, national governments, and universities have jointly developed a variety of vaccines. …”
Get full text

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates by Nihan Izat, Jayaprakasam Bolleddula, Pasquale Carione, Leticia Huertas Valentin, Robert S. Jones, Priyanka Kulkarni, Darren Moss, Vincent C. Peterkin, Dan‐Dan Tian, Andrea Treyer, Karthik Venkatakrishnan, Michael A. Zientek, Jill Barber, J. Brian Houston, Aleksandra Galetin, Daniel Scotcher

Get full text

Prevalence of Pharmaceuticals in Surface Water Samples in Ghana by David Azanu, David Adu-Poku, Selina Ama Saah, William Ofori Appaw

“…The estimated risk quotient values for antibiotics resistance were above 1 for all the antibiotics investigated in surface water impacted by the wastewater of hospitals and pharmaceutical companies’ except surface water impacted by sewage treatment plants (STPs) and market wastewater. …”
Get full text

Evolutionary game and simulation analysis of tripartite subjects in public health emergencies under government reward and punishment mechanisms by Dandan Gao, Wei Guo

“…The research findings indicate that (1) For the tripartite entities of public health emergencies, the key for strategy choices is to reduce the gain obtained from illegal production and non-cooperation with prevention and control. (2) The strength of the initial willingness to participate has a significant effect on the evolution strategies of each subject. (3) For pharmaceutical companies and the public, the incentives and penalties of local governments can promote the former’s compliance and the latter’s cooperation in prevention and control. …”
Get full text

Quantitative estimation of drugs for erectile dysfunction and benign prostatic hyperplasia by high performance liquid chromatography: a review by Shalaka G. Gaonkar, Basavaraj M Dinnimath

“…By emphasizing the importance of HPLC in maintaining high analytical standards for ED and BPH drug analysis, this review serves as a valuable resource for researchers, clinicians, and pharmaceutical companies, ultimately aiming to enhance drug management and improve patient outcomes through better analytical practices and innovative approaches. …”
Get full text

Deciphering the Role of Artificial Intelligence in Medical Sciences: An Update by Siddhant Khanna, Merajul Haque Siddiqui, Shalini Bhushan, Rahul Saxena

“…AI is becoming more and more of a versatile actor in the medical sciences, spanning all specializations and including diagnostics. Pharmaceutical companies, payers, and healthcare providers are already using various forms of AI. …”
Get full text

Ethics on Compulsion of Vaccinations in the Age of COVID-19 by Tsuriel Rashi

“…In December 2020, several pharmaceutical companies announced that they had succeeded in producing effective vaccines and after approval by the various regulatory bodies, countries started to vaccinate their citizens. …”
Get full text

Risk Assessment for Complex Systems Based on Fuzzy Cognitive Maps: A Case of the Biopharmaceutical Industry by Hadi Abbasian, Reza Yousefi-Zenouz, Abdollah Amirkhani, Masoud Shirzadeh, Akbar Abdollahiasl, Shekoufeh Nikfar, Mohammadreza Siahi-Shadabad, Abbas Kebriaeezadeh

“…The proposed FCM features and the knowledge gained from evaluating them can provide practical and helpful information to pharmaceutical companies to deal with their supply risks more efficiently.…”
Get full text

Canadian Standards Association Standard CAN/CSA/Z264.1-02:2002: A New Voluntary Standard for Spacers and Holding Chambers Used with Pressurized Metered-Dose Inhalers by Myrna B Dolovich, Jolyon P Mitchell

“…This consensus standard was developed with the support of pharmaceutical companies and manufacturers of spacers and holding chambers, and with the help of clinicians, retail pharmacists and representatives of patient advocate bodies associated with respiratory diseases and the dissemination of information related to the treatment and the delivery of inhaled medications. …”
Get full text

Pervasive systemic disparities: medical-related gaslighting, trauma, and distrust among LGBTQ+ people in the United States by Dustin Z. Nowaskie, Dehandra Blackwood, Frank Garcia

“…Likewise, LGBTQ+ people conveyed significantly less trust (ORs 0.46–0.53) in primary care providers (59.8% vs. 74.1%), medical specialists (56.5% vs. 71.7%), pharmaceutical companies (17% vs. 28%), insurance companies (15.9% vs. 29.3%), and U.S. healthcare systems (17.8% vs. 30.4%).DiscussionMedical-related gaslighting, trauma, and distrust are pervasive systemic disparities among LGBTQ+ people. …”
Get full text

Opportunities for sustainable waste management in the pharmaceutical industry declaration of competing interest by Nikolić Branislava, Nikolić Nađa, Milošević Anica, Milošević-Georgiev Andrijana

“…Positive changes in the sustainability of the pharmaceutical industry cannot be achieved without active collaboration involving pharmaceutical companies, academia, and policymakers. The scientific community should intensively explore possibilities for sustainable pharmaceutical waste management. …”
Get full text

Potential risks to the National Health Service (NHS) of a Post-Brexit US Trade Deal by Louise Dalingwater

“…Moreover, in late November 2019, Jeremy Corbyn contended that Conservatives were negotiating a secret trade deal containing clauses which would open the NHS up to American pharmaceutical companies. The central focus of this paper is thus to examine the likely consequences of a post-Brexit trade deal between the US and the UK and to consider to what extent it could undermine the UK’s ability to provide a free, universal public health service. …”
Get full text

Considering the impact of vaccine communication in the COVID-19 pandemic among adults in Canada: A qualitative study of lessons learned for future vaccine campaigns by Jeanna Parsons Leigh, Stephana Julia Moss, Jade MacDonald, Michal S. Cherak, Henry T. Stelfox, Ève Dubé, Kirsten M. Fiest, Donna M. Halperin, Sofia B. Ahmed, Shannon E. MacDonald, Sharon E. Straus, Terra Manca, Josh Ng Kamstra, Andrea Soo, Scott A. Halperin

“…Moreover, participants highlighted a lack of trust in the information provided by government agencies and pharmaceutical companies, primarily driven by concerns regarding their underlying motives. …”
Get full text